The Commission supports Member States in reducing the burden of non-communicable diseases (NCDs), including hyperemesis gravidarum (HG), under the framework of the ‘Healthier Together’ EU NCDs initiative[1].

Financial support from the EU4Health programme[2] is provided for actions under the initiative, which must include a health equity dimension and address different groups’ needs, including women.

The Commission also supports the collection and transfer of best and promising practices among Member States via the EU Best Practice Portal on Public Health[3].

The Public Health Expert Group[4] assists the Commission, including on the preparation of policy and legislative initiatives and activities addressing major public health challenges.

The proposed reform of the EU pharmaceutical legislation[5], currently under negotiation, promotes the development of innovative medicines including for unmet medical needs. Measures provide dedicated regulatory support[6] for those medicines as well as targeted incentives.

The EU is at the forefront of supporting research and innovation (R&I) to improve and protect health and well-being of citizens. Over EUR 1.3 billion have been invested in more than 700 R&I projects related to women’s health, including gynaecological-related diseases, through the EU’s R&I framework programmes, Horizon 2020[7] and Horizon Europe[8].

Specific funding for R&I into HG under Horizon Europe is not currently planned. Horizon Europe, however, offers a variety of funding opportunities, including calls for collaborative proposals under its cluster 1 ‘Health’ Work Programme 2025.[9] There is more information on opportunities for further research on women’s health and gynaecological diseases[10].

Last updated: 2 July 2025